Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Palliative Care × Dermatologic × Clear all

Phase

Phase NA 1 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 4 Genitourinary 2 Thoracic 1 Other solid neoplasm 1 Other hematologic neoplasm 1 Dermatologic 1

Conditions

Interventions

Ipilimumab 100 Nivolumab 99 pembrolizumab 98 aldesleukin 68 Cyclophosphamide 62 fludarabine phosphate 46 Interleukin-2 42 Temozolomide 32 Dacarbazine 32 trametinib 31 Bevacizumab 28 fludarabine 27 dabrafenib 27 Radiotherapy 26 sargramostim 24 incomplete Freund's adjuvant 24 Vemurafenib 24 Radiosurgery 24 Paclitaxel 20 Carboplatin 20 binimetinib 18 atezolizumab 18 Aminolevulinic Acid 18 encorafenib 17 Peripheral Blood Stem Cell Transplantation 17 Biopsy 17 Mycophenolic Acid 16 cobimetinib 15 HhAntag691 15 Whole-Body Irradiation 14

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02645149 2026-02-27

Match Mel

Melanoma Institute Australia

Phase 2 Completed

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡